DR. AVIK DEY SARKAR

Dr. SANJAY KUMAR DAULAT THAKUR, Dr. SMARANJIT BISWAS, DR. SANCHARI SARKAR

Abstract

Aim: To assess efficiency and safety of Oral Eplerenone in Acute Central Serous Chorioretinopathy (CSCR).

Methods: Among 162 patients of acute CSCR, 81 received oral Eplerenone (Group A) and 81 received Placebo therapy (Group B). BCVA, Central macular thickness (CMT) and serum K+ were measured at baseline and monthly for 3 months.

Results: Change in CMT in Group A and Group B were 278.8µ and 206.9µ in 1st month(p=0.006), 328.28µ and 240.02µ (p=0.001) in 2nd month and 360.7µ and 278.25µ in 3rd month (p=0.002) respectively. Average BCVA improvement in Group A and Group B were 6.05 lines and 4.21 lines at conclusion respectively(p=0.021). 3.7% in Group A progressed to chronic CSCR compared to 17.3% patients in Group B. Increase in Serum K+ at conclusion was 0.62mg% in Group A and negligible in Group B (p=0.035).

Conclusion: Eplerenone is a safe and effective first-line treatment option for acute CSCR conferring higher and faster resolution with protection from progression to chronicity.

Full Text